GPCR19 Agonist Composition for Allergic Dermatitis Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for atopic dermatitis, such as anti-histamines and steroids, have significant side effects and do not provide long-term relief, making them inadequate for effectively managing the chronic nature of the condition.
Innovation Solution
A pharmaceutical composition containing a G protein-coupled receptor 19 (GPCR19) agonist, specifically sodium taurodeoxycholate (HY2191) and its derivatives, is developed for use in oral, injection, and external preparations to treat and prevent allergic skin diseases by reducing serum IgE levels and modulating T lymphocyte function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-histamines or steroids are used to treat atopic dermatitis, then symptoms are relieved, but side effects occur and symptoms recur when administration is stopped
Solution Approach 1:
The patent changes the pharmacological parameter by using a GPCR19 agonist (sodium taurodeoxycholate) instead of conventional anti-histamines or steroids. This new mechanism of action provides symptom relief while avoiding the harmful side effects associated with traditional treatments, such as skin atrophy, facial flushing, and systemic effects like hypoadrenocorticism and diabetes.
Solution Approach 2:
The patent converts the harmful effect of recurrent symptoms upon discontinuation into a benefit by developing a treatment that provides sustained relief. The GPCR19 agonist modulates immune response in a way that maintains symptom control even after administration stops, eliminating the need for continuous use to prevent recurrence.
2Reliability
If steroid ointments are applied for long term, then atopic dermatitis is controlled, but serious side effects such as skin atrophy and facial flushing occur
Solution Approach 1:
The patent introduces a GPCR19 agonist as an intermediary substance that mediates the treatment effect. Instead of directly suppressing immunity like steroids, the GPCR19 agonist acts through a different pathway to control inflammation and itch, providing disease control without causing skin atrophy or facial flushing.
Solution Approach 2:
The patent replaces the mechanical action of steroid ointments (direct immune suppression) with a biochemical mechanism involving GPCR19 activation. This substitution allows for sustained disease control through a different physiological pathway that does not produce harmful local effects.
3Object-generated harmful factors
If calcineurin inhibitors are used, then steroid side effects are avoided, but carcinogenesis risk increases and market size decreases
Solution Approach 1:
The patent changes the therapeutic parameter by using a GPCR19 agonist instead of calcineurin inhibitors. This new mechanism provides the advantage of avoiding steroid side effects while eliminating the carcinogenesis risk associated with calcineurin inhibitors, as the GPCR19 pathway does not involve the same immunosuppressive mechanisms that carry cancer risk.
4Loss of energy
If medication dosage is reduced or administration is stopped, then long-term use is avoided, but symptoms usually recur
Solution Approach 1:
The patent achieves continuity of useful action through the GPCR19 agonist mechanism. The treatment maintains symptom control even when dosage is reduced or administration is stopped, as the GPCR19 activation provides sustained modulation of the immune response that prevents symptom recurrence without requiring continuous high-dose treatment.
Data Source
AI summary
The present invention is about a pharmaceutical composition, an oral preparation, and an injection preparation containing a G protein-coupled Receptor19 (GPCR19) agonist, specifically sodium taurodeoxycholate (HY2191) and its derivative, as an active ingredient for preventing or treating allergic skin diseases. The present invention is also about an external preparation and a cosmetic composition containing said pharmaceutical composition for preventing and improving allergic skin diseases. The said pharmaceutical composition shows an excellent efficacy in treating and improving allergic dermatitis compared with the steroid ointments or immunosuppressive ointments currently used. The said pharmaceutical composition reduces the level of serum IgE, which is a major factor causing allergic dermatitis, increases TH1 cytokine alleviating allergic dermatitis and reduces TH2 cytokine that exacerbates allergic dermatitis. The said pharmaceutical composition also reduces infiltration of a mast cell, eosinophil, and neutrophil in dermis and ameliorates clinical symptoms such as erythema, hemorrhage, edema, excoriation, erosion, scaling and dryness. Thus, the said pharmaceutical composition can be used to prevent and treat allergic skin diseases.